EPIDAREX CAPITAL – CATALYZING INNOVATION IN HEALTH SCIENCE AND TECHNOLOGY

Month: September 2024

Enterprise Therapeutics granted ‘rare pediatric disease designation’ in the US for novel cystic fibrosis investigational therapy ETD001

September 27, 2024

Brighton, UK, 26 September 2024: Enterprise Therapeutics Ltd (Enterprise), a biopharmaceuticalcompany dedicated to the discovery and development of novel therapies to improve the lives of

Read »

Harness Therapeutics Appoints Experienced R&D Executive and Physician-Scientist, Dr Paulo Fontoura, as Non-Executive Director

September 4, 2024

Dr Paulo Fontoura brings 20 years’ experience of working in the pharma industry, with the most recent 16 years focusing on translational medicine and clinical

Read »

EPIDAREX CAPITAL – CATALYZING INNOVATION IN HEALTH SCIENCE AND TECHNOLOGY

Month: September 2024

Enterprise Therapeutics granted ‘rare pediatric disease designation’ in the US for novel cystic fibrosis investigational therapy ETD001

Harness Therapeutics Appoints Experienced R&D Executive and Physician-Scientist, Dr Paulo Fontoura, as Non-Executive Director

Categories

Archives